Fordadistrogene movaparvovec is a gene therapy treatment for people with Duchenne muscular dystrophy, manufactured by the pharmaceutical company Pfizer.
It is currently in the early steps in the NICE appraisal process. The timelines for the next steps are currently unknown and more detail will be available in due course.
MDUK will be monitoring for any further developments and feed into the appraisal when it opens.
For more information on NICE’s assessment of Fordadistrogene movaparvovec can be found here.